The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Lung cancer updates at ASCO 2021
David R. Spigel, MD, Sarah Cannon Research Institute, Nashville, TN, shares exciting updates in lung cancer at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, including the results from the Phase III IMpower010 (NCT02486718) trial of adjuvant atezolizumab in patients with stage IB to IIIA non–small cell lung cancer (NSCLC). Preliminary results showed the primary endpoint of overall survival (OS) was met and approval of adjuvant atezolizumab may lead to increased incorporation of immunotherapy in early-stage lung cancer. This interview took place at the ASCO 2021 Virtual Meeting.
